Related references
Note: Only part of the references are listed.Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
Daniele Generali et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer
C. Holm et al.
JOURNAL OF PATHOLOGY (2009)
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy
M. Zoubir et al.
ANNALS OF ONCOLOGY (2008)
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
Lisa Ryden et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Predictive markers in breast cancer - the present
S. J. L. Payne et al.
HISTOPATHOLOGY (2008)
Phosphorylation of estrogen receptor-α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients
Jie Jiang et al.
CLINICAL CANCER RESEARCH (2007)
A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen
Jingwei Cheng et al.
ENDOCRINOLOGY (2007)
Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
N. Sarwar et al.
ENDOCRINE-RELATED CANCER (2006)
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
Caroline Holm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen
Jenny Bergqvist et al.
EUROPEAN JOURNAL OF CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
L Rydén et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer
H Yamashita et al.
BREAST CANCER RESEARCH (2005)
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
L Ryden et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phospho-serine-118 estrogen receptor-α detection in human breast tumors in vivo
L Murphy et al.
CLINICAL CANCER RESEARCH (2004)
Phospho-serine-118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen
LC Murphy et al.
CLINICAL CANCER RESEARCH (2004)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Share Paper
